Sara Carrillo de Albornoz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara Carrillo de Albornoz has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Dennis Petrie
Centre for Health Economics, Monash University, Melbourne, Australia
5 shared publicationsAlisa M. Higgins
Australian and New Zealand Intensive Care Research Centre Monash University Melbourne Australia
4 shared publicationsAdam Irving
Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
3 shared publicationsErica M. Wood
School of Public Health and Preventive Medicine Monash University Melbourne Australia
3 shared publications- Erica M. Wood
School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
3 shared publications Zoe K. McQuilten
School of Public Health and Preventive Medicine Monash University Melbourne Australia
3 shared publications
Latest Publications
- Open Access
- 21 May 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 275-285
The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time‐driven activity‐based costing study
Summary: Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time‐driven activity‐based costing study at a large Australian university teaching hospital. Every activity relating to RBC transfusion in patients with MDS was observed and process‐mapped, ranging from patient pre‐transfusion phlebotomy through to laboratory processes, clinical transfusion in inpatient and outpatient wards, clinical follow‐up and transfusion governance and oversight. For each activity, detailed data collection was undertaken, including timing of individual steps and recording all consumables, equipment and personnel involved. The total per‐unit cost was US$440.47, with an annual per‐patient estimated cost of US$6607.12. Hospital‐related costs contributed 41% of the total cost, with the largest contributor being equipment (16%) followed by staffing (14%). Alloimmunisation increased process costs by 24%. These findings demonstrate that hospital process costs need to be included when considering and budgeting for the total cost of the transfusion process. Our findings will inform future transfusion‐related resourcing and cost‐effectiveness evaluations of treatments which aim to reduce RBC transfusion burden and improve quality of life in MDS.
- 21 May 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 275-285
Open AccessThe true cost of red cell transfusion for patients with myelodysplastic syndromes: A time‐driven activity‐based costing study
Summary: Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time‐driven activity‐based costing study at a large Australian university teaching hospital. Every activity relating to RBC transfusion in patients with MDS was observed and process‐mapped, ranging from patient pre‐transfusion phlebotomy through to laboratory processes, clinical transfusion in inpatient and outpatient wards, clinical follow‐up and transfusion governance and oversight. For each activity, detailed data collection was undertaken, including timing of individual steps and recording all consumables, equipment and personnel involved. The total per‐unit cost was US$440.47, with an annual per‐patient estimated cost of US$6607.12. Hospital‐related costs contributed 41% of the total cost, with the largest contributor being equipment (16%) followed by staffing (14%). Alloimmunisation increased process costs by 24%. These findings demonstrate that hospital process costs need to be included when considering and budgeting for the total cost of the transfusion process. Our findings will inform future transfusion‐related resourcing and cost‐effectiveness evaluations of treatments which aim to reduce RBC transfusion burden and improve quality of life in MDS.
- Open Access
- 28 March 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (4) , 382
Intravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing
Purpose: Prophylactic immunoglobulin (Ig) is used to prevent infections in patients with hypogammaglobulinaemia due to haematological malignancies (HM). Ig can be administered intravenously (IVIg) in hospital or self-administered subcutaneously (SCIg) at home, using different dosing regimens but with comparable effectiveness. In Australia, Ig product costs alone were AU$915.7 million in 2022/2023, 60% of the national blood budget. However, the total cost of IVIg and SCIg, including administration costs, remains uncertain. Methods: We conducted a prospective, time-driven, activity-based costing study to compare the costs of providing IVIg and SCIg to patients with HM from an Australian healthcare perspective. Ig product, consumables, equipment, and in-hospital costs were included. Analyses were conducted assuming full adherence and using (1) published prices for IVIg and SCIg, which excluded plasma fractionation costs to the Australian government, and (2) equivalent average weighted price for IVIg and SCIg, including plasma fractionation costs. Results: Annual IVIg product cost per patient was lower than that for SCIg under both costing scenarios: (1) AU$10,012 and (2) AU$5895, driven by higher SCIg doses. The costs of treating a patient with IVIg for a year were (1) AU$9936 and (2) AU$5787 lower than with SCIg, mainly due to higher SCIg product costs. When only in-hospital administration costs were considered (excluding Ig product and SCIg home consumables), SCIg treatment was AU$1019 less costly than IVIg. Conclusion: Our results indicated higher annual direct costs per patient treated with SCIg than IVIg, despite higher in-hospital costs associated with IVIg administration. Further research, including understanding costs to patients, is warranted.
- 28 March 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (4) , 382
Open AccessIntravenous versus subcutaneous immunoglobulin in patients with haematological malignancies: time-driven activity-based costing
Purpose: Prophylactic immunoglobulin (Ig) is used to prevent infections in patients with hypogammaglobulinaemia due to haematological malignancies (HM). Ig can be administered intravenously (IVIg) in hospital or self-administered subcutaneously (SCIg) at home, using different dosing regimens but with comparable effectiveness. In Australia, Ig product costs alone were AU$915.7 million in 2022/2023, 60% of the national blood budget. However, the total cost of IVIg and SCIg, including administration costs, remains uncertain. Methods: We conducted a prospective, time-driven, activity-based costing study to compare the costs of providing IVIg and SCIg to patients with HM from an Australian healthcare perspective. Ig product, consumables, equipment, and in-hospital costs were included. Analyses were conducted assuming full adherence and using (1) published prices for IVIg and SCIg, which excluded plasma fractionation costs to the Australian government, and (2) equivalent average weighted price for IVIg and SCIg, including plasma fractionation costs. Results: Annual IVIg product cost per patient was lower than that for SCIg under both costing scenarios: (1) AU$10,012 and (2) AU$5895, driven by higher SCIg doses. The costs of treating a patient with IVIg for a year were (1) AU$9936 and (2) AU$5787 lower than with SCIg, mainly due to higher SCIg product costs. When only in-hospital administration costs were considered (excluding Ig product and SCIg home consumables), SCIg treatment was AU$1019 less costly than IVIg. Conclusion: Our results indicated higher annual direct costs per patient treated with SCIg than IVIg, despite higher in-hospital costs associated with IVIg administration. Further research, including understanding costs to patients, is warranted.
- Open Access
- 3 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71397
Cost of Serious Infections in Chronic Lymphocytic Leukemia
Background: The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events. Infections are among the most common adverse events in CLL patients, resulting from immune dysregulation caused by both the underlying disease and treatments. Immunoglobulin replacement therapy (IgRT) is one prophylactic measure used to prevent infections, but its effectiveness in CLL is unclear and costs are substantial. The aim of this paper was to estimate the excess cost associated with serious infections in patients with CLL, and explore other factors that may increase hospitalization costs in Australia. Methods: We conducted a retrospective longitudinal study of linked hospital data, including 3705 patients with CLL and hospital admissions between July 2016 and June 2022. We estimated the excess cost associated with serious infections, inhospital anticancer treatment and IgRT using generalized linear models with gamma distribution and identity link. Results: Over the study period, the mean inhospital cost per patient per month was AU$1291 (US$892) and was highest in the month of CLL diagnosis, at AU$4168 (US$2880). The excess cost in the month of a serious infection was AU$22,905 (US$15,829) per patient, and costs remained higher in the subsequent 6 months. The monthly costs associated with IgRT and anticancer treatment were AU$3288 (US$2772) and AU$5223 (US$3609) per patient, respectively. Conclusion: Our results highlight the high economic burden of serious infections in a large cohort of patients with CLL over a 6‐year period. Further costing studies including costs to the patient and healthcare utilization in the outpatient setting are needed to ascertain the total cost of infections and the overall cost of cancer care in patients with CLL.
- 3 February 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (2) , e71397
Open AccessCost of Serious Infections in Chronic Lymphocytic Leukemia
Background: The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events. Infections are among the most common adverse events in CLL patients, resulting from immune dysregulation caused by both the underlying disease and treatments. Immunoglobulin replacement therapy (IgRT) is one prophylactic measure used to prevent infections, but its effectiveness in CLL is unclear and costs are substantial. The aim of this paper was to estimate the excess cost associated with serious infections in patients with CLL, and explore other factors that may increase hospitalization costs in Australia. Methods: We conducted a retrospective longitudinal study of linked hospital data, including 3705 patients with CLL and hospital admissions between July 2016 and June 2022. We estimated the excess cost associated with serious infections, inhospital anticancer treatment and IgRT using generalized linear models with gamma distribution and identity link. Results: Over the study period, the mean inhospital cost per patient per month was AU$1291 (US$892) and was highest in the month of CLL diagnosis, at AU$4168 (US$2880). The excess cost in the month of a serious infection was AU$22,905 (US$15,829) per patient, and costs remained higher in the subsequent 6 months. The monthly costs associated with IgRT and anticancer treatment were AU$3288 (US$2772) and AU$5223 (US$3609) per patient, respectively. Conclusion: Our results highlight the high economic burden of serious infections in a large cohort of patients with CLL over a 6‐year period. Further costing studies including costs to the patient and healthcare utilization in the outpatient setting are needed to ascertain the total cost of infections and the overall cost of cancer care in patients with CLL.
- Open Access
- 20 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5367-5377
Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.
- 20 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5367-5377
Open AccessImmunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.
- Open Access
- 1 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (S1) , S106
PD23 Economic Evaluation Of Prophylactic Immunoglobulin Versus Prophylactic Antibiotics In Hematological Malignancies: Results From The RATIONAL Feasibility Trial
Introduction: Patients with hematological malignancies are at high risk of infections due to both the disease and the associated treatments. The use of immunoglobulin (Ig) to prevent infections is increasing in this population, but its cost effectiveness is unknown. This trial-based economic evaluation aimed to compare the cost effectiveness of prophylactic Ig with prophylactic antibiotics in patients with hematological malignancies.Methods: The economic evaluation used individual patient data from the RATIONAL feasibility trial, which randomly assigned 63 adults with chronic lymphocytic leukemia, multiple myeloma, or lymphoma to prophylactic Ig or prophylactic antibiotics. The following two analyses were conducted to estimate the cost effectiveness of the two treatments over the 12-month trial period from the perspective of the Australian health system:(i) a cost-utility analysis (CUA) to assess the incremental cost per quality-adjusted life-year (QALY) gained using data collected with the EuroQol 5D-5L questionnaire; and(ii) a cost-effectiveness analysis (CEA) to assess the incremental cost per serious infection prevented (grade ≥3) and per infection prevented (any grade).Results: The total cost per patient was significantly higher in the Ig arm than in the antibiotic arm (difference AUD29,140 [USD19,000]). There were non-significant differences in health outcomes between the treatment arms: patients treated with Ig had fewer QALYs (difference −0.072) and serious infections (difference −0.26) than those given antibiotics, but more overall infections (difference 0.76). The incremental cost-effectiveness from the CUA indicated that Ig was more costly than antibiotics and associated with fewer QALYs. In the CEA, Ig costed an additional AUD111,262 (USD73,000) per serious infection prevented, but it was more costly than antibiotics and associated with more infections when all infections were included.Conclusions: These results indicate that, on average, Ig prophylactic treatment may not be cost effective compared with prophylactic antibiotics for the group of patients with hematological malignancies recruited to the RATIONAL feasibility trial. Further research is needed to confirm these findings in a larger population and over the longer term.
- 1 December 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (S1) , S106
Open AccessPD23 Economic Evaluation Of Prophylactic Immunoglobulin Versus Prophylactic Antibiotics In Hematological Malignancies: Results From The RATIONAL Feasibility Trial
Introduction: Patients with hematological malignancies are at high risk of infections due to both the disease and the associated treatments. The use of immunoglobulin (Ig) to prevent infections is increasing in this population, but its cost effectiveness is unknown. This trial-based economic evaluation aimed to compare the cost effectiveness of prophylactic Ig with prophylactic antibiotics in patients with hematological malignancies.Methods: The economic evaluation used individual patient data from the RATIONAL feasibility trial, which randomly assigned 63 adults with chronic lymphocytic leukemia, multiple myeloma, or lymphoma to prophylactic Ig or prophylactic antibiotics. The following two analyses were conducted to estimate the cost effectiveness of the two treatments over the 12-month trial period from the perspective of the Australian health system:(i) a cost-utility analysis (CUA) to assess the incremental cost per quality-adjusted life-year (QALY) gained using data collected with the EuroQol 5D-5L questionnaire; and(ii) a cost-effectiveness analysis (CEA) to assess the incremental cost per serious infection prevented (grade ≥3) and per infection prevented (any grade).Results: The total cost per patient was significantly higher in the Ig arm than in the antibiotic arm (difference AUD29,140 [USD19,000]). There were non-significant differences in health outcomes between the treatment arms: patients treated with Ig had fewer QALYs (difference −0.072) and serious infections (difference −0.26) than those given antibiotics, but more overall infections (difference 0.76). The incremental cost-effectiveness from the CUA indicated that Ig was more costly than antibiotics and associated with fewer QALYs. In the CEA, Ig costed an additional AUD111,262 (USD73,000) per serious infection prevented, but it was more costly than antibiotics and associated with more infections when all infections were included.Conclusions: These results indicate that, on average, Ig prophylactic treatment may not be cost effective compared with prophylactic antibiotics for the group of patients with hematological malignancies recruited to the RATIONAL feasibility trial. Further research is needed to confirm these findings in a larger population and over the longer term.
- Open Access
- 16 May 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (1) , e32-23
A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies
Objectives: Patients with hematological malignancies are likely to develop hypogammaglobulinemia. Immunoglobulin (Ig) is commonly given to prevent infections, but its overall costs and cost-effectiveness are unknown. Methods: A systematic review was conducted following the PRISMA guidelines to assess the evidence on the costs and cost-effectiveness of Ig, administered intravenously (IVIg) or subcutaneously (SCIg), in adults with hematological malignancies. Results: Six studies met the inclusion criteria, and only two economic evaluations were identified; one cost-utility analysis (CUA) of IVIg versus no Ig, and another comparing IVIg with SCIg. The quality of the evidence was low. Compared to no treatment, Ig reduced hospitalization rates. One study reported no significant change in hospitalizations following a program to reduce IVIg use, and an observational study comparing IVIg with SCIg suggested that there were more hospitalizations with SCIg but lower overall costs per patient. The CUA comparing IVIg versus no Ig suggested that IVIg treatment was not cost-effective, and the other CUA comparing IVIg to SCIg found that home-based SCIg was more cost-effective than IVIg, but both studies had serious limitations. Conclusions: Our review highlighted key gaps in the literature: the cost-effectiveness of Ig in patients with hematological malignancies is very uncertain. Despite increasing Ig use worldwide, there are limited data regarding the total direct and indirect costs of treatment, and the optimal use of Ig and downstream implications for healthcare resource use and costs remain unclear. Given the paucity of evidence on the costs and cost-effectiveness of Ig treatment in this population, further health economic research is warranted.
- 16 May 2024
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 40 (1) , e32-23
Open AccessA systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies
Objectives: Patients with hematological malignancies are likely to develop hypogammaglobulinemia. Immunoglobulin (Ig) is commonly given to prevent infections, but its overall costs and cost-effectiveness are unknown. Methods: A systematic review was conducted following the PRISMA guidelines to assess the evidence on the costs and cost-effectiveness of Ig, administered intravenously (IVIg) or subcutaneously (SCIg), in adults with hematological malignancies. Results: Six studies met the inclusion criteria, and only two economic evaluations were identified; one cost-utility analysis (CUA) of IVIg versus no Ig, and another comparing IVIg with SCIg. The quality of the evidence was low. Compared to no treatment, Ig reduced hospitalization rates. One study reported no significant change in hospitalizations following a program to reduce IVIg use, and an observational study comparing IVIg with SCIg suggested that there were more hospitalizations with SCIg but lower overall costs per patient. The CUA comparing IVIg versus no Ig suggested that IVIg treatment was not cost-effective, and the other CUA comparing IVIg to SCIg found that home-based SCIg was more cost-effective than IVIg, but both studies had serious limitations. Conclusions: Our review highlighted key gaps in the literature: the cost-effectiveness of Ig in patients with hematological malignancies is very uncertain. Despite increasing Ig use worldwide, there are limited data regarding the total direct and indirect costs of treatment, and the optimal use of Ig and downstream implications for healthcare resource use and costs remain unclear. Given the paucity of evidence on the costs and cost-effectiveness of Ig treatment in this population, further health economic research is warranted.
- Open Access
- 14 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (9) , 2259-2267
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive, and its cost-effectiveness compared with other prevention strategies remains unknown. We conducted a trial–based economic evaluation from the Australian health care system perspective to estimate the 12-month cost-effectiveness of prophylactic Ig vs prophylactic antibiotics in 63 adults with HGG and hematological malignancies participating in the RATIONAL feasibility trial. Two analyses were conducted: (1) cost-utility analysis to assess the incremental cost per quality-adjusted life year (QALY) gained; and (2) cost-effectiveness analysis to assess the incremental cost per serious infection prevented (grade ≥3) and per any infection (any grade) prevented. Over 12 months, the total cost per patient was significantly higher in the Ig group than in the antibiotic group (mean difference, AU$29 140; P < .001). Most patients received IVIg, which was the main cost driver; only 2 patients in the intervention arm received subcutaneous Ig. There were nonsignificant differences in health outcomes. Results showed Ig was more costly than antibiotics and associated with fewer QALYs. The incremental cost-effectiveness ratio of Ig vs antibiotics was AU$111 262 per serious infection prevented, but Ig was more costly and associated with more infections when all infections were included. On average and for this patient population, Ig prophylaxis may not be cost-effective compared with prophylactic antibiotics. Further research is needed to confirm these findings in a larger population and considering longer-term outcomes. The trial was registered at the Australian and New Zealand Clinical Trials Registry as #ACTRN12616001723471.
- 14 May 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (9) , 2259-2267
Open AccessEconomic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
Patients with hematological malignancies are at high risk of developing hypogammaglobulinemia (HGG) and infections. Immunoglobulin (Ig) is one recommended option to prevent these infections, but it is expensive, and its cost-effectiveness compared with other prevention strategies remains unknown. We conducted a trial–based economic evaluation from the Australian health care system perspective to estimate the 12-month cost-effectiveness of prophylactic Ig vs prophylactic antibiotics in 63 adults with HGG and hematological malignancies participating in the RATIONAL feasibility trial. Two analyses were conducted: (1) cost-utility analysis to assess the incremental cost per quality-adjusted life year (QALY) gained; and (2) cost-effectiveness analysis to assess the incremental cost per serious infection prevented (grade ≥3) and per any infection (any grade) prevented. Over 12 months, the total cost per patient was significantly higher in the Ig group than in the antibiotic group (mean difference, AU$29 140; P < .001). Most patients received IVIg, which was the main cost driver; only 2 patients in the intervention arm received subcutaneous Ig. There were nonsignificant differences in health outcomes. Results showed Ig was more costly than antibiotics and associated with fewer QALYs. The incremental cost-effectiveness ratio of Ig vs antibiotics was AU$111 262 per serious infection prevented, but Ig was more costly and associated with more infections when all infections were included. On average and for this patient population, Ig prophylaxis may not be cost-effective compared with prophylactic antibiotics. Further research is needed to confirm these findings in a larger population and considering longer-term outcomes. The trial was registered at the Australian and New Zealand Clinical Trials Registry as #ACTRN12616001723471.
- 14 December 2023
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 39 (S1) , S26-S27
OP95 A Systematic Review Of The Cost And Cost Effectiveness Of Immunoglobulin Treatment In Patients With Hematological Malignancies
IntroductionPatients with hematological malignancies are likely to develop hypogammaglobulinemia (HGG) and subsequent infections. Immunoglobulin (Ig) replacement is commonly given to prevent infections, but the total costs and cost effectiveness of its use are unknown.MethodsA systematic review was conducted following PRISMA guidelines to assess evidence on the costs and cost effectiveness of Ig replacement, administered intravenously (IVIg) or subcutaneously (SCIg), in adult patients with hematological malignancies. This review was registered with PROSPERO (CRD42022321908).ResultsSix studies were included out of a total of 3,612 citations. A narrative synthesis was conducted because of the high level of heterogeneity across the included studies. Two economic evaluations were identified: one cost-utility analysis (CUA) of IVIg versus no Ig and one comparing IVIg with SCIg. The quality of the evidence was low, with most studies having small patient numbers and a high risk of bias. Compared with no treatment, Ig replacement reduced the hospitalization rate in patients with hematological malignancies.One study reported no change in hospitalization rates following a program to reduce IVIg use, and an observational study comparing IVIg with SCIg found more hospitalizations with SCIg but lower total costs per patient. The CUA comparing IVIg with no IVIg suggested that IVIg treatment was not cost effective, but this study was published in 1991 and had significant limitations. The other CUA found that home-based SCIg was more cost effective than IVIg, but model inputs were derived from unpublished data in a very small patient cohort with HGG and different malignancies.ConclusionsOur review highlights key gaps in the literature. The cost effectiveness of Ig replacement in patients with hematological malignancies is still very uncertain. Despite the increasing use of Ig replacement there are limited data regarding its direct and indirect costs, and its optimal use and implications for healthcare resources remain unclear. Given the paucity of data on the cost and cost effectiveness of Ig treatment in this population, further health economic research is warranted.
- 14 December 2023
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 39 (S1) , S26-S27
OP95 A Systematic Review Of The Cost And Cost Effectiveness Of Immunoglobulin Treatment In Patients With Hematological Malignancies
IntroductionPatients with hematological malignancies are likely to develop hypogammaglobulinemia (HGG) and subsequent infections. Immunoglobulin (Ig) replacement is commonly given to prevent infections, but the total costs and cost effectiveness of its use are unknown.MethodsA systematic review was conducted following PRISMA guidelines to assess evidence on the costs and cost effectiveness of Ig replacement, administered intravenously (IVIg) or subcutaneously (SCIg), in adult patients with hematological malignancies. This review was registered with PROSPERO (CRD42022321908).ResultsSix studies were included out of a total of 3,612 citations. A narrative synthesis was conducted because of the high level of heterogeneity across the included studies. Two economic evaluations were identified: one cost-utility analysis (CUA) of IVIg versus no Ig and one comparing IVIg with SCIg. The quality of the evidence was low, with most studies having small patient numbers and a high risk of bias. Compared with no treatment, Ig replacement reduced the hospitalization rate in patients with hematological malignancies.One study reported no change in hospitalization rates following a program to reduce IVIg use, and an observational study comparing IVIg with SCIg found more hospitalizations with SCIg but lower total costs per patient. The CUA comparing IVIg with no IVIg suggested that IVIg treatment was not cost effective, but this study was published in 1991 and had significant limitations. The other CUA found that home-based SCIg was more cost effective than IVIg, but model inputs were derived from unpublished data in a very small patient cohort with HGG and different malignancies.ConclusionsOur review highlights key gaps in the literature. The cost effectiveness of Ig replacement in patients with hematological malignancies is still very uncertain. Despite the increasing use of Ig replacement there are limited data regarding its direct and indirect costs, and its optimal use and implications for healthcare resources remain unclear. Given the paucity of data on the cost and cost effectiveness of Ig treatment in this population, further health economic research is warranted.
- Top Cited Papers
- 19 July 2021
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 39 (1) , 168-182
The effectiveness of teleconsultations in primary care: systematic review
Background: The COVID-19 pandemic has focussed attention on models of healthcare that avoid face-to-face contacts between clinicians and patients, and teleconsultations have become the preferred mode of primary care delivery. However, the effectiveness of remote consultations in this setting remains unclear. Objective: To evaluate the impact of telephone or video consultations compared to those conducted face-to-face on key patient-relevant outcomes and healthcare utilisation in primary care, mental health and allied health services, which have had a critical role in the management of the wider and longer-term consequences of COVID-19. Methods: A systematic review of primary studies comparing telephone or video consultations versus face-to-face visits, following the PRISMA guidelines. Results: Overall, consultations delivered by telephone and videoconference were as effective as face-to-face in-person visits to improve clinical outcomes in adults with mental health conditions and those attending primary care services. Patient satisfaction with telephone and video consultations and the therapeutic alliance was high across the studies. However, high discontinuation rates in patients receiving teleconsultations indicate this may not be a suitable modality of healthcare delivery for all patients. Teleconsultations offer significant patient time savings in primary care, but appropriate implementation, including training of healthcare professionals and management of technical issues, is essential to ensure effective and valuable clinical interventions. Conclusions: Teleconsultations via telephone or videoconference are an effective alternative to face-to-face consultations for many patients attending primary care and mental health services. Teleconsultations have the potential to deliver time-efficient and lower-cost interventions at a distance while improving access to healthcare.
- 19 July 2021
- Published by Oxford University Press (OUP) in Family Practice
- Vol. 39 (1) , 168-182
Top Cited PapersThe effectiveness of teleconsultations in primary care: systematic review
Background: The COVID-19 pandemic has focussed attention on models of healthcare that avoid face-to-face contacts between clinicians and patients, and teleconsultations have become the preferred mode of primary care delivery. However, the effectiveness of remote consultations in this setting remains unclear. Objective: To evaluate the impact of telephone or video consultations compared to those conducted face-to-face on key patient-relevant outcomes and healthcare utilisation in primary care, mental health and allied health services, which have had a critical role in the management of the wider and longer-term consequences of COVID-19. Methods: A systematic review of primary studies comparing telephone or video consultations versus face-to-face visits, following the PRISMA guidelines. Results: Overall, consultations delivered by telephone and videoconference were as effective as face-to-face in-person visits to improve clinical outcomes in adults with mental health conditions and those attending primary care services. Patient satisfaction with telephone and video consultations and the therapeutic alliance was high across the studies. However, high discontinuation rates in patients receiving teleconsultations indicate this may not be a suitable modality of healthcare delivery for all patients. Teleconsultations offer significant patient time savings in primary care, but appropriate implementation, including training of healthcare professionals and management of technical issues, is essential to ensure effective and valuable clinical interventions. Conclusions: Teleconsultations via telephone or videoconference are an effective alternative to face-to-face consultations for many patients attending primary care and mental health services. Teleconsultations have the potential to deliver time-efficient and lower-cost interventions at a distance while improving access to healthcare.